Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders
Neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and Huntington’s disease, due to their multifaced and complicated nature, remain uncurable and impose substantial financial and human burdens on society. Therefore, developing new innovative therapeutic strategies is vital. In this conte...
Saved in:
| Main Authors: | Kiarash Eskandari, Sara-Maude Bélanger, Véronik Lachance, Saïd Kourrich |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/5/700 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacological and Pathological Implications of Sigma-1 Receptor in Neurodegenerative Diseases
by: Noah Drewes, et al.
Published: (2025-06-01) -
Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging
by: Ping Bai, et al.
Published: (2025-06-01) -
Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
by: Xiaoan Wei, et al.
Published: (2022-05-01) -
Broad-spectrum antiviral activity of the sigma-1 receptor antagonist PB28 against coronaviruses
by: Gaojie Song, et al.
Published: (2025-08-01) -
The effect of acupuncture stimulation on alleviating emotional changes due to acute alcohol administration and the possibility of sigma1 receptor involvement
by: Su Yeon Seo, et al.
Published: (2021-06-01)